Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when delivered concurrently with radiotherapy in women with recu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakomy, David S., Urbauer, Diana L., Westin, Shannon N., Lin, Lilie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974697/
https://www.ncbi.nlm.nih.gov/pubmed/31993510
http://dx.doi.org/10.1016/j.ctro.2019.12.005
Descripción
Sumario:PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when delivered concurrently with radiotherapy in women with recurrent gynecologic cancers.

Ejemplares similares